Dr. Benjamin Miles completed his PhD in Nanophysics at the University of Bristol in 2016. Following his PhD, Dr. Miles joined Ziylo as Lead Physicist to commercialise a diabetes therapeutic later acquired for $800m by Novo Nordisk. Dr. Miles supported the launch of Unit DX, Bristol’s first science incubation facility before launching his own company Spin Up Science with the goal of supporting scientists and engineers’ efforts to translate their research into the market. In 2021, Dr. Miles cofounded the Science Angel Syndicate to support investment into ventures emerging from academic institutions.